Lantheus Holdings, Inc.(LNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LNTH Lantheus Holdings, Inc.

盘前交易 03-24 09:25:10 EDT

75.73

-0.70

-0.92%

盘前75.20

-0.53-0.70%

09:09 EDT

最高78.04	最低75.40	成交量89.17万
今开77.43	昨收76.43	日振幅3.45%
总市值49.30亿	流通市值45.39亿	总股本6,510万
成交额6,789万	换手率1.49%	流通股本5,994万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LNTH","market":"US","secType":"STK","nameCN":"Lantheus Holdings, Inc.","latestPrice":75.73,"timestamp":1774296000000,"preClose":76.43,"halted":0,"volume":891693,"hourTrading":{"tag":"盘前","latestPrice":75.2,"preClose":75.73,"latestTime":"09:09 EDT","volume":69,"amount":5323.38036,"timestamp":1774357752673,"change":-0.53,"changeRate":-0.006999,"amplitude":0.034465},"delay":0,"changeRate":-0.00915870731388202,"floatShares":59936726,"shares":65102599,"eps":3.41,"marketStatus":"盘前交易","change":-0.7,"latestTime":"03-24 09:25:10 EDT","open":77.43,"high":78.04,"low":75.4,"amount":67893308.84754,"amplitude":0.034541,"askPrice":77.99,"askSize":24,"bidPrice":66.65,"bidSize":410,"shortable":3,"etf":0,"ttmEps":3.41,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774359000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1435204800000,"exchange":"NASDAQ","adjPreClose":75.73,"preHourTrading":{"tag":"盘前","latestPrice":75.2,"preClose":75.73,"latestTime":"09:09 EDT","volume":69,"amount":5323.38036,"timestamp":1774357752673,"change":-0.53,"changeRate":-0.006999,"amplitude":0.034465},"postHourTrading":{"tag":"盘后","latestPrice":75.73,"preClose":75.73,"latestTime":"19:53 EDT","volume":44820,"amount":3394195.9124,"timestamp":1774309996844,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8231235184518149,"impliedVol":0.4677,"impliedVolPercentile":0.356},"requestUrl":"/m/hq/s/LNTH","defaultTab":"news","newsList":[{"id":"1190539000","title":"Lantheus宣布PET诊断成像试剂盒LNTH-2501（Ga 68 Edotreotide）的PDUFA日期延长三个月，该产品靶向生长抑素受体阳性（SSTR+）神经内分泌肿瘤（NETs）","url":"https://stock-news.laohu8.com/highlight/detail?id=1190539000","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190539000?lang=zh_cn&edition=full","pubTime":"2026-03-18 04:04","pubTimestamp":1773777882,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc.近日宣布，其针对生长抑素受体阳性神经内分泌肿瘤的PET诊断成像试剂盒LNTH-2501的处方药用户付费法案目标日期已获得美国食品药品监督管理局延长三个月。此次延期为FDA提供了更多时间来完成对该公司新药申请的审查。公司表示，将继续与FDA密切合作，以支持该申请的最终审查。此次PDUFA日期的延长并不反映FDA对该申请的任何负面看法，也不预示最终的审查结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNTH","BK4585","BK4588","BK4198"],"gpt_icon":0},{"id":"2617382658","title":"Lantheus Holdings, Inc.盘中异动 急速下跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617382658","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617382658?lang=zh_cn&edition=full","pubTime":"2026-03-07 01:26","pubTimestamp":1772818005,"startTime":"0","endTime":"0","summary":"北京时间2026年03月07日01时26分，Lantheus Holdings, Inc.股票出现异动，股价急速下挫5.18%。Lantheus Holdings, Inc.股票所在的制药行业中，整体跌幅为1.27%。Lantheus Holdings, Inc.公司简介：Lantheus Holdings Inc 通过开发诊断产品迎合美国医疗保健行业的需求。Precision Diagnostic 产品帮助医疗保健专业人员查找和跟踪疾病，重点是心脏病学。战略合作伙伴关系侧重于通过使用生物标志物、数字解决方案和制药服务平台实现精准医疗， 还包括向 Bausch Health Companies, Inc 授予 RELISTOR 许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030701264597a8c077&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030701264597a8c077&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LNTH","BK4585","BK4588","BK4198"],"gpt_icon":0},{"id":"1162262861","title":"异动解读 | Lantheus获FDA药物暂时批准，股价盘中大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162262861","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162262861?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:07","pubTimestamp":1772464036,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc.（股票代码：LNTH）今日盘中股价大幅上涨5.07%，引起了市场的高度关注。消息面上，Lantheus Holdings, Inc.宣布其研发的Lutetium Lu 177 Dotatate（研发代号Pnt2003）已获得美国食品药品监督管理局（FDA）的暂时批准。该药物在放射性方面与已上市的Lutathera®具有等效性，这一积极进展被视为公司产品管线的重要里程碑，增强了投资者对其未来增长潜力的信心，从而推动了股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LNTH"],"gpt_icon":0},{"id":"1178118628","title":"Lantheus获FDA暂时批准Lutetium Lu 177 Dotatate (Pnt2003)，放射性等效于Lutathera®","url":"https://stock-news.laohu8.com/highlight/detail?id=1178118628","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178118628?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:31","pubTimestamp":1772458282,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc.宣布，其研发的Lutetium Lu 177 Dotatate（研发代号Pnt2003）已获得美国食品药品监督管理局（FDA）的暂时批准。该药物在放射性方面与已上市的Lutathera®具有等效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4198","BK4585","LNTH"],"gpt_icon":0},{"id":"1143649582","title":"财报前瞻 ｜Lantheus Holdings, Inc.本季度营收预计减0.02，机构观点谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1143649582","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143649582?lang=zh_cn&edition=full","pubTime":"2026-02-19 12:31","pubTimestamp":1771475506,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc.将于2026年02月26日盘前发布最新季度财报，市场聚焦营收与调整后每股收益的同比变化及盈利质量走向。市场一致预期本季度公司营收为3.68亿美元，同比为-0.02；调整后每股收益为1.17，同比为-0.24；息税前利润为1.09亿美元，同比为-0.29；当前尚无针对毛利率或净利率的公开一致预测。从公开一致预期与公司披露的财报会议安排来看，卖方对本季度的业绩判断整体偏谨慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻 ｜Lantheus Holdings, Inc.本季度营收预计减0.02，机构观点谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNTH"],"gpt_icon":0},{"id":"1139663079","title":"Lantheus Holdings, Inc.：Truist Securities将评级从持有上调至买入；目标价从61美元上调至80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139663079","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139663079?lang=zh_cn&edition=full","pubTime":"2025-12-12 13:03","pubTimestamp":1765515800,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc.：Truist Securities将评级从持有上调至买入；目标价从61美元上调至80美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","BK4585","BK4588","LNTH"],"gpt_icon":0},{"id":"2585212409","title":"Lantheus Holdings, Inc.盘中异动 临近午盘股价大涨5.00%报56.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585212409","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585212409?lang=zh_cn&edition=full","pubTime":"2025-11-22 00:31","pubTimestamp":1763742709,"startTime":"0","endTime":"0","summary":"北京时间2025年11月22日00时31分，Lantheus Holdings, Inc.股票出现异动，股价快速上涨5.00%。Lantheus Holdings, Inc.股票所在的制药行业中，整体涨幅为1.00%。Lantheus Holdings, Inc.公司简介：Lantheus Holdings Inc 通过开发诊断产品迎合美国医疗保健行业的需求。Precision Diagnostic 产品帮助医疗保健专业人员查找和跟踪疾病，重点是心脏病学。战略合作伙伴关系侧重于通过使用生物标志物、数字解决方案和制药服务平台实现精准医疗， 还包括向 Bausch Health Companies, Inc 授予 RELISTOR 许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112200314995130604&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112200314995130604&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4198","BK4585","LNTH"],"gpt_icon":0},{"id":"1177291789","title":"Lantheus 宣布领导层过渡计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1177291789","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177291789?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:58","pubTimestamp":1763571530,"startTime":"0","endTime":"0","summary":"11月6日 - Lantheus Holdings Inc.宣布领导层过渡计划。Lantheus Holdings Inc. - Brian Markison 将退休，结束首席执行官职务；董事会正在寻找下一任首席执行官。Lantheus Holdings Inc. - Mary Anne Heino 被任命为执行主席，自2025年11月7日起生效。Lantheus Holdings Inc. - Mary Anne Heino 将担任公司临时首席执行官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","LNTH","BK4585","BK4588"],"gpt_icon":0},{"id":"1175595983","title":"Lantheus Holdings第三季度调整后每股收益为1.27美元，与IBES预估一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1175595983","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175595983?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:57","pubTimestamp":1763571430,"startTime":"0","endTime":"0","summary":"11月6日 - Lantheus Holdings第三季度自由现金流为9470万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNTH","BK4585","BK4588","BK4198"],"gpt_icon":0},{"id":"1125427887","title":"异动解读 | Lantheus Holdings股价盘中大跌5.50%，CEO宣布退休","url":"https://stock-news.laohu8.com/highlight/detail?id=1125427887","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125427887?lang=zh_cn&edition=full","pubTime":"2025-11-06 23:54","pubTimestamp":1762444455,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc.今日盘中股价大跌5.50%，引发市场关注。这一显著下跌似乎与公司高层变动有关。据悉，Lantheus Holdings, Inc.的首席执行官Brian Markison宣布退休，公司董事会已开始寻找新任CEO。值得注意的是，尽管股价下跌，Lantheus Holdings, Inc.最近的财务表现似乎并不差。公司刚刚公布的第三季度财报显示，调整后每股收益为1.27美元，符合市场预期。同时，第三季度自由现金流达到9470万美元，显示公司仍保持良好的现金生成能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LNTH"],"gpt_icon":0},{"id":"1173901694","title":"异动解读 | 蓝特斯控股(LNTH)发布强劲季报，盘前大涨9.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173901694","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173901694?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:28","pubTimestamp":1762432104,"startTime":"0","endTime":"0","summary":"周四盘前，医疗保健公司蓝特斯控股股价大幅上涨9.73%，引起投资者广泛关注。这一显著涨幅主要归因于公司发布的强劲第三季度财务业绩。根据公司公告，蓝特斯控股第三季度调整后每股收益达到1.27美元，符合IBES预期。值得注意的是，蓝特斯控股在第三季度实现了9470万美元的自由现金流。这一财务指标的优异表现可能是推动股价大幅上涨的另一个关键因素。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LNTH"],"gpt_icon":0},{"id":"1149510540","title":"Lantheus Holdings第三季度调整后每股收益为1.27美元，符合IBES预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1149510540","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149510540?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:15","pubTimestamp":1762431359,"startTime":"0","endTime":"0","summary":"11月6日 - Lantheus Holdings第三季度自由现金流为9470万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4198","LNTH"],"gpt_icon":0},{"id":"1114518494","title":"Lantheus Holdings, Inc. - Brian Markison 宣布退休，董事会开始寻找新任首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1114518494","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114518494?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:01","pubTimestamp":1762430474,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc. - Brian Markison 宣布退休，董事会开始寻找新任首席执行官","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LNTH","BK4585","BK4198"],"gpt_icon":0},{"id":"1185405456","title":"Lantheus宣布FDA授予Lnth-2501（Ga 68 Edotreotide）上市申请的PDUFA日期，旨在诊断靶向生长抑素受体阳性（SSTR+）神经内分泌肿瘤（NETs）的PET影像学工具","url":"https://stock-news.laohu8.com/highlight/detail?id=1185405456","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185405456?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:30","pubTimestamp":1761827438,"startTime":"0","endTime":"0","summary":"Lantheus宣布FDA授予Lnth-2501（Ga 68 Edotreotide）上市申请的PDUFA日期，旨在诊断靶向生长抑素受体阳性（SSTR+）神经内分泌肿瘤（NETs）的PET影像学工具。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4198","LNTH"],"gpt_icon":0},{"id":"1122505732","title":"Lantheus宣布FDA受理Mk-6240新药申请，这是一种针对阿尔茨海默病Tau的PET影像剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1122505732","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122505732?lang=zh_cn&edition=full","pubTime":"2025-10-28 20:30","pubTimestamp":1761654614,"startTime":"0","endTime":"0","summary":"Lantheus宣布FDA已受理其Mk-6240的新药申请，该药物是一种针对阿尔茨海默病中Tau蛋白的PET影像剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4198","LNTH"],"gpt_icon":0},{"id":"1122758925","title":"Lantheus Holdings, Inc.与GE Healthcare就前列腺癌成像剂Pylarify®(氟化吡氟叶酸F 18)在日本市场签署独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1122758925","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122758925?lang=zh_cn&edition=full","pubTime":"2025-09-24 13:02","pubTimestamp":1758690142,"startTime":"0","endTime":"0","summary":"Lantheus Holdings, Inc.与GE Healthcare宣布，双方就前列腺癌成像剂Pylarify®(氟化吡氟叶酸F 18)在日本市场的商业化达成独家许可协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4198","LNTH","BK4588"],"gpt_icon":0},{"id":"2517943630","title":"Lantheus Holdings, Inc.涨2.00% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2517943630","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517943630?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:49","pubTimestamp":1741186195,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时49分，Lantheus Holdings, Inc.股票出现波动，股价大幅上涨2.00%。Lantheus Holdings, Inc.股票所在的制药行业中，整体涨幅为0.79%。Lantheus Holdings, Inc.公司简介：Lantheus Holdings Inc 通过开发诊断产品迎合美国医疗保健行业的需求。战略合作伙伴关系侧重于通过使用生物标志物、数字解决方案和制药服务平台实现精准医疗，还包括向 Bausch Health Companies, Inc 授予 RELISTOR 许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224955a260ce20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224955a260ce20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4198","LNTH","BK4585"],"gpt_icon":0},{"id":"2516548063","title":"Lantheus Holdings, Inc.2024财年实现净利润3.12亿美元，同比减少4.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516548063","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516548063?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:00","pubTimestamp":1740931236,"startTime":"0","endTime":"0","summary":"3月3日，Lantheus Holdings, Inc.公布财报，公告显示公司2024财年净利润为3.12亿美元，同比减少4.59%；其中营业收入为15.34亿美元，同比增加18.36%，每股基本收益为4.52美元。机构评级：截至2025年3月3日，当前有14家机构对Lantheus Holdings, Inc.目标价做出预测，其中目标均价为131.11美元，其中最低目标价为94.50美元，最高目标价为166.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000056abe4aca3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000056abe4aca3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LNTH"],"gpt_icon":0},{"id":"1178569921","title":"异动解读 | 2024年业绩超出预期,朗修盘中大涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178569921","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178569921?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:43","pubTimestamp":1740581038,"startTime":"0","endTime":"0","summary":"朗修控股(LNTH)今日盘中大涨5.15%,引起了市场的广泛关注。\n\n消息面上,朗修公布了2024年第四季度业绩,每股收益为1.59美元,高于分析师预期的1.53美元,增长3.92%;季度销售额为3.911亿美元,也超出分析师预期的3.754亿美元,增长4.17%。\n\n另外,该公司还发布了2025年的业绩预期,预计全年营收为15.45亿至16.1亿美元,市场之前预期为16.05亿美元;预计调整后每股收益为7.00至7.20美元,高于市场预期的6.95美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LNTH"],"gpt_icon":0},{"id":"2514856927","title":"Lantheus Holdings, Inc.盘中异动 早盘股价大涨5.35%报84.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856927","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514856927?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:31","pubTimestamp":1740580290,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时31分，Lantheus Holdings, Inc.股票出现波动，股价大幅拉升5.35%。Lantheus Holdings, Inc.股票所在的制药行业中，整体跌幅为0.13%。Lantheus Holdings, Inc.公司简介：Lantheus Holdings Inc 通过开发诊断产品迎合美国医疗保健行业的需求。战略合作伙伴关系侧重于通过使用生物标志物、数字解决方案和制药服务平台实现精准医疗，还包括向 Bausch Health Companies, Inc 授予 RELISTOR 许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022622313096314f22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022622313096314f22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4198","BK4585","LNTH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lantheus.com","stockEarnings":[{"period":"1week","weight":-0.0353},{"period":"1month","weight":0.0252},{"period":"3month","weight":0.1383},{"period":"6month","weight":0.4227},{"period":"1year","weight":-0.225},{"period":"ytd","weight":0.1379}],"compareEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0494},{"period":"3month","weight":-0.0474},{"period":"6month","weight":-0.0087},{"period":"1year","weight":0.1621},{"period":"ytd","weight":-0.0389}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Lantheus Holdings, Inc.于2007年成立于特拉华州，总部在马萨诸塞州的北比尔里卡。公司是从事开发、生产、销售及分销创新医学影像诊断试剂和产品，协助临床医生在心血管和其他疾病的诊断的全球领导者。公司的试剂通常用于诊断冠状动脉疾病、充血性心脏衰竭、中风、外周血管疾病和其他疾病。临床医生使用公司的显像剂和产品通过一系列的成像方式,包括核成像、超声心动图和磁共振成像,或核磁共振。公司相信改进的诊断信息能够使医疗服务提供更好的检测和表征,或排除疾病,可能实现改善病人状况、减少病人风险和限制纳税人整体成本和整个医疗体系。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":-0.020476},{"month":2,"riseRate":0.727273,"avgChangeRate":0.191228},{"month":3,"riseRate":0.636364,"avgChangeRate":0.019938},{"month":4,"riseRate":0.9,"avgChangeRate":0.074197},{"month":5,"riseRate":0.6,"avgChangeRate":0.007739},{"month":6,"riseRate":0.7,"avgChangeRate":0.134294},{"month":7,"riseRate":0.545455,"avgChangeRate":0.040337},{"month":8,"riseRate":0.454545,"avgChangeRate":0.065065},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.049956},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.045273},{"month":11,"riseRate":0.818182,"avgChangeRate":0.076347},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.040744}],"exchange":"NASDAQ","name":"Lantheus Holdings, Inc.","nameEN":"Lantheus"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lantheus Holdings, Inc.(LNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Lantheus Holdings, Inc.(LNTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Lantheus Holdings, Inc.,LNTH,Lantheus Holdings, Inc.股票,Lantheus Holdings, Inc.股票老虎,Lantheus Holdings, Inc.股票老虎国际,Lantheus Holdings, Inc.行情,Lantheus Holdings, Inc.股票行情,Lantheus Holdings, Inc.股价,Lantheus Holdings, Inc.股市,Lantheus Holdings, Inc.股票价格,Lantheus Holdings, Inc.股票交易,Lantheus Holdings, Inc.股票购买,Lantheus Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lantheus Holdings, Inc.(LNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Lantheus Holdings, Inc.(LNTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}